Theracryf (TCF)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 0.000p
   
  • Closing Price Chg:
      0.000p
  • 52 Week High: 0.000p
  • 52 Week Low: 0.000p
  • Currency: UK Pounds
  • Shares Issued: 2,148.96m
  • Volume: 0

Theracryf Overview

TheraCryf is a clinical stage therapeutics company developing a new generation of innovative therapeutics in oncology and behavioural brain disorders. TheraCryf’s strategy is to generate compelling data sets with a goal of partnering its programmes with mid-size to large pharma. The Company’s clinical asset is SFX-01, a patented sulforaphane-based medicine. Chronos’ neuropsychiatry assets use novel chemistry to address highly relevant targets in brain health and have composition of matter patent cover. The Group Company has the expertise to develop and commercialise the combined portfolio.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn n/a n/a
ROCE n/a  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue n/a n/a
Pr/Book 0.8  
Latest F'cast
Revenue n/a n/a
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

Theracryf Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Mar-21 0.19 (3.21) (1.82)p n/a n/a n/a n/a 0.0%
31-Mar-22 n/a (3.17) (0.99)p n/a n/a n/a n/a 0.0%
31-Mar-23 0.44 (5.01) 1.47p 2.5 n/a n/a n/a 0.0%
31-Mar-24 0.40 (3.57) (1.14)p n/a n/a n/a n/a 0.0%
31-Mar-25 n/a (2.09) (0.36)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Theracryf Company Announcements

Director/PDMR Shareholding 16-Oct-2025 16:45 RNS
Holding(s) in Company 16-Oct-2025 16:45 RNS
Holding(s) in Company 26-Sep-2025 15:45 RNS

Theracryf ShareCast News

TheraCryf signs deal for Ox-1 addiction treatmen... 12-May-2025 ShareCast
Evgen upbeat on start of glioblastoma research p... 26-Oct-2023 ShareCast
Evgen Pharma doses first volunteers in SFX-01 tr... 16-Nov-2022 ShareCast

Latest Theracryf Director Deals

Traded Action Notifier PriceAmountValue
14-Oct-25 Buy Edward Wardle 0.18p 7,342,296 £12,849.02

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 3: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 4: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 5: Forecast figures based on normalised accounts.

 

Theracryf Market Data

Currency UK Pounds
Share Price 0.000p
Closing Price Change 0.000p
% Change 0.00 %
52 Week High 0.000p
52 Week Low 0.000p
Volume 0
Shares Issued 2,148.96m

Theracryf Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
13.79% above the market average13.79% above the market average13.79% above the market average13.79% above the market average13.79% above the market average
90.24% above the sector average90.24% above the sector average90.24% above the sector average90.24% above the sector average90.24% above the sector average
Price Trend
86.93% below the market average86.93% below the market average86.93% below the market average86.93% below the market average86.93% below the market average
72.73% below the sector average72.73% below the sector average72.73% below the sector average72.73% below the sector average72.73% below the sector average
Income Not Available
Growth Not Available

Theracryf Dividends

No dividends found

Trades for 21-Oct-2025

Time Volume / Share Price
15:16 5,686 @ 0.22p
12:57 4,545 @ 0.22p
09:52 39,126 @ 0.22p
09:11 200,000 @ 0.21p

Theracryf Key Personnel

CEO Huw Jones
CFO Toni Hänninen

Top of Page